Patrick Fortune - PAREXEL International Independent Director

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

Dr. Patrick J. Fortune, Ph.D., is Independent Director of Parexel International Corporationrationration. is Chairman of the Human Resources Committee and a member of the Audit and Finance Committee and the Compensation Committee. Since September 2014, Dr. Fortune has served as Sector LeaderSenior Advisor, Innovation of Partners Healthcare. From June 2012 to September 2014, he served as Senior General Manager of Innovations at The Cleveland Clinic, an educational medical center. Since September 2001, Dr. Fortune has served as a Partner of Boston Millennia Partners, a VC firm. From September 2001 to June 2005, he served as Executive Chairman of Knowledge Impact Systems, Inc., a software end user training company. From April 1999 to June 2001, he served as President, Chief Operating Officer and a director of New Era of Networks, Inc., an Internet software and services company. From October 1995 to March 1999, Dr. Fortune was Vice President, Information Technology and Chief Information Officer of Monsanto Company, an agricultural, pharmaceutical and food products company. From August 1994 to July 1995, Dr. Fortune was President and Chief Operating Officer, Chief Information Officer and a member of the Board of Directors of Coram Healthcare Corporationrationration, a medical therapy services company. From December 1991 to August 1994, Dr. Fortune was Corporationrationrate Vice President, Information Management at BristolMyers Squibb, a pharmaceutical company. Prior to that, Dr. Fortune was Senior Vice President and General Manager of Packaging Corporationrationration of America, a subsidiary of Tenneco, and held several management positions with Baxter International, Inc., including Corporationrationrate Vice President President, Parenteral Products Division Vice President, Research and Development and Vice President, Information Services. Dr. Fortune also served on the boards of directors of CombinatoRx, Incorporated from 2006 to 2009 and EPIX Pharmaceuticals, Inc. from 2006 to 2008.
Age: 68  Director Since 1996      
781 487-9900

Patrick Fortune Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Geoffery MerszeiOrigin Agritech Limited
Sridar IyengarDr Reddys Laboratories Ltd
Shlomo YanaiPerrigo Company plc
Larry CordellOrigin Agritech Limited
Bradley AlfordPerrigo Company plc
Prasad MenonDr Reddys Laboratories Ltd
Bharat DoshiDr Reddys Laboratories Ltd
Paul BisaroZoetis
Pengfei LiSinovac Biotech Ltd
Margaret McGlynnVertex Pharmaceuticals Incorpor
Shikha SharmaDr Reddys Laboratories Ltd
Leo PuriDr Reddys Laboratories Ltd
Simon AndersonSinovac Biotech Ltd
Gregory NordenZoetis
William YoungVertex Pharmaceuticals Incorpor
Jianzeng CaoSinovac Biotech Ltd
Michael BrownRegeneron Pharmaceuticals
David AltshulerVertex Pharmaceuticals Incorpor
Marc TessierLavigneRegeneron Pharmaceuticals
Theodore SamuelstoPerrigo Company plc
Ashok GangulyDr Reddys Laboratories Ltd

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Center Now


Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 50 shares of
few hours ago
Traded for 1.0
Purchased over 50 shares of
few hours ago
Traded for 1.0
Purchased over 10K shares of
few hours ago
Traded for 1.0
Purchased over 10K shares of
few hours ago
Traded for 1.0
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.